XML 146 R2.htm IDEA: XBRL DOCUMENT
v3.25.1

Pay vs Performance Disclosure - USD ($) | 12 Months Ended
--- | ---
Dec. 31, 2024 | Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020
Pay vs Performance Disclosure [Table] |  |  |  |  |  |
Pay vs Performance Disclosure, Table |  | ## Pay versus Performance Pursuant to the Dodd-Frank Act and Item 402(v) of Regulation S-K, we are required to provide the following information regarding the relationship between executive compensation paid to our named executive officers and Vericel’s financial performance for each of the last five completed calendar years. In determining the Compensation Actually Paid (or “CAP”) to our Principal Executive Officer, who is our CEO, and our other named executive officers, we are required to make various adjustments to the amounts that have been previously reported in the Summary Compensation Table, as summarized below. The CAP amounts reflected in the table below do not reflect the actual amount of compensation earned by or paid to our named executive officers during the applicable year. For information regarding decisions made by our Compensation Committee with respect to executive compensation, refer to the “Compensation Discussion and Analysis” section of this Proxy Statement. Total Net Revenue
|  | Summary Compensation Table Total for CEO |  |  | Compensation Actually Paid to CEO(1) |  |  | Average Summary Compensation Table Total for Other NEOs(2) |  |  | Average Compensation Actually Paid to Other NEOs(1)(2) |  |  | Value of Initial $100 Investment Based On: |  |  |  |  |  |  |
Year |  |  |  |  |  |  |  |  |  | Vericel TSR(3) |  |  | NASDAQ Biotechnology Index TSR(3) |  |  | Net Income ($M)(4) |  |  | Total Net Revenue ($M)(5) |
2024 |  | $ | 10,237,525 |  |  | $ | 18,758,303 |  |  | $ | 2,703,655 |  |  | $ | 4,246,598 |  |  | $ | 316 |  |  | $ | 114 |  |  | $ | 10 |  |  | $ | 237 |
2023 |  | $ | 7,056,422 |  |  | $ | 11,004,672 |  |  | $ | 1,918,083 |  |  | $ | 2,851,775 |  |  | $ | 205 |  |  | $ | 115 |  |  | $ | -3 |  |  | $ | 198 |
2022 |  | $ | 8,708,367 |  |  | $ | 905,166 |  |  | $ | 2,398,900 |  |  | $ | 467,192 |  |  | $ | 151 |  |  | $ | 111 |  |  | $ | -17 |  |  | $ | 164 |
2021 |  | $ | 13,183,295 |  |  | $ | 15,233,917 |  |  | $ | 3,459,670 |  |  | $ | 3,204,518 |  |  | $ | 226 |  |  | $ | 125 |  |  | $ | -7 |  |  | $ | 156 |
2020 |  | $ | 4,412,718 |  |  | $ | 10,300,425 |  |  | $ | 1,158,216 |  |  | $ | 1,740,344 |  |  | $ | 177 |  |  | $ | 126 |  |  | $ | 3 |  |  | $ | 124 |
(1) | To calculate CAP, the following amounts were deducted from and added to the applicable Summary Compensation Table total compensation:
(2) | The other NEOs in each covered year were as follows: 2024 – Joe Mara, Michael Halpin, Sean Flynn, Jonathan Hopper, Karen Mahoney; 2023 – Joe Mara, Michael Halpin, Jonathan Hopper, Sean Flynn; 2022 – Joe Mara, Michael Halpin, Sean Flynn, Jonathan Hopper; 2021 – Joe Mara, Michael Halpin, Sean Flynn, Jonathan Hopper, Sandra Pennell; 2020 – Michael Halpin, Sean Flynn, Jonathan Hopper, Gerard Michel, Sandra Pennell.
(3) | TSR is cumulative for the measurement period, calculated in accordance with Item 201(e) of Regulation S-K. Our TSR Peer Group are members of the NASDAQ Biotechnology Index.
(4) | Reflects net Income as shown in the Company’s Annual Report on Form 10-K for the years ending on December 31, 2024, 2023, 2022, 2021 and 2020.
(5) | Reflects total net revenue, the “company-selected measure” as shown in the Company’s Annual Report on Form 10-K for the years ending on December 31, 2024, 2023, 2022, 2021 and 2020.
|  |  |  | CEO
|  |  |  | 2020 |  |  | 2021 |  |  | 2022 |  |  | 2023 |  |  | 2024 |
|  | Summary Compensation Table Total |  | $ | 4,412,718 |  |  | $ | 13,183,295 |  |  | $ | 8,708,367 |  |  | $ | 7,056,422 |  |  | $ | 10,237,525 |
Less: |  | Grant Date Fair Value of Stock and Option Awards in the Covered Year |  | -$ | 3,218,783 |  |  | -$ | 11,819,409 |  |  | -$ | 7,288,603 |  |  | -$ | 5,513,083 |  |  | -$ | 8,680,435 |
Plus: |  | Fair Value at Year-End of Unvested Stock and Option Awards Granted in the Covered Year* |  | +$ | 5,022,331 |  |  | +$ | 6,387,501 |  |  | +$ | 4,402,751 |  |  | +$ | 5,834,763 |  |  | +$ | 8,700,718 |
Plus: |  | Fair Value of Stock and Option Awards Granted in the Covered Year that Vested in the Covered Year* |  | +$ | 522,347 |  |  | +$ | 1,618,248 |  |  | +$ | 724,137 |  |  | +$ | 711,181 |  |  | +$ | 1,038,836 |
|  | Change in Fair Value of Unvested Stock and Option Awards Granted in Prior Years* |  | +$ | 3,550,577 |  |  | +$ | 1,965,721 |  |  | -$ | 3,564,080 |  |  | +$ | 1,963,617 |  |  | +$ | 4,861,123 |
|  | Change in Fair Value of Stock and Option Awards from Prior Years that Vested in the Covered Year* |  | +$ | 11,235 |  |  | +$ | 3,898,560 |  |  | -$ | 2,077,406 |  |  | +$ | 951,771 |  |  | +$ | 2,600,537 |
= |  | Compensation Actually Paid |  | $ | 10,300,425 |  |  | $ | 15,233,917 |  |  | $ | 905,166 |  |  | $ | 11,004,672 |  |  | $ | 18,758,303 |
|  |  |  | Average of Other NEOs
|  |  |  | 2020 |  |  | 2021 |  |  | 2022 |  |  | 2023 |  |  | 2024 |
|  | Summary Compensation Table Total |  | $ | 1,158,216 |  |  | $ | 3,459,670 |  |  | $ | 2,398,900 |  |  | $ | 1,918,083 |  |  | $ | 2,703,655 |
Less: |  | Grant Date Fair Value of Stock and Option Awards in the Covered Year |  | -$ | 714,993 |  |  | -$ | 2,945,499 |  |  | -$ | 1,748,862 |  |  | -$ | 1,198,907 |  |  | -$ | 2,049,743 |
Plus: |  | Fair Value at Year-End of Unvested Stock and Option Awards Granted in the Covered Year* |  | +$ | 756,348 |  |  | +$ | 1,626,544 |  |  | +$ | 1,056,425 |  |  | +$ | 1,275,999 |  |  | +$ | 2,095,233 |
Plus: |  | Fair Value of Stock and Option Awards Granted in the Covered Year that Vested in the Covered Year* |  | +$ | 83,133 |  |  | +$ | 271,626 |  |  | +$ | 173,955 |  |  | +$ | 147,705 |  |  | +$ | 180,724 |
|  | Change in Fair Value of Unvested Stock and Option Awards Granted in Prior Years* |  | +$ | 636,734 |  |  | +$ | 299,760 |  |  | -$ | 902,246 |  |  | +$ | 445,775 |  |  | +$ | 832,854 |
|  | Change in Fair Value of Stock and Option Awards from Prior Years that Vested in the Covered Year* |  | +$ | 5,675 |  |  | +$ | 594,099 |  |  | -$ | 510,980 |  |  | +$ | 263,119 |  |  | +$ | 483,874 |
Less: |  | Fair Value of Stock and Option Awards Forfeited During the Covered Year* |  | -$ | 184,769 |  |  | -$ | 101,683 |  |  | +$ | 0 |  |  | +$ | 0 |  |  | +$ | 0 |
= |  | Compensation Actually Paid |  | $ | 1,740,344 |  |  | $ | 3,204,518 |  |  | $ | 467,192 |  |  | $ | 2,851,775 |  |  | $ | 4,246,598 |
| * | All stock option valuations included in “Compensation Actually Paid” values were performed using the Black-Scholes option pricing model in a manner generally consistent with the process used to determine stock option grant date fair values under ASC718 (refer to our Annual Report on Form 10-K for the year ending December 31, 2024 for additional detail).
(2) | The other NEOs in each covered year were as follows:
| 2024 – Joe Mara, Michael Halpin, Sean Flynn, Jonathan Hopper, Karen Mahoney; 2023 – Joe Mara, Michael Halpin, Jonathan Hopper, Sean Flynn; 2022 – Joe Mara, Michael Halpin, Sean Flynn, Jonathan Hopper; 2021 – Joe Mara, Michael Halpin, Sean Flynn, Jonathan Hopper, Sandra Pennell; 2020 – Michael Halpin, Sean Flynn, Jonathan Hopper, Gerard Michel, Sandra Pennell.
(3) | TSR is cumulative for the measurement period, calculated in accordance with Item 201(e) of Regulation S-K. Our TSR Peer Group are members of the NASDAQ Biotechnology Index.
(4) | Reflects net Income as shown in the Company’s Annual Report on Form 10-K for the years ending on December 31, 2024, 2023, 2022, 2021 and 2020.
(5) | Reflects total net revenue, the “company-selected measure” as shown in the Company’s Annual Report on Form 10-K for the years ending on December 31, 2024, 2023, 2022, 2021 and 2020.
Company Selected Measure Name |  | Total Net Revenue |  |  |  |
Named Executive Officers, Footnote |  |
(2) | The other NEOs in each covered year were as follows:
| 2024 – Joe Mara, Michael Halpin, Sean Flynn, Jonathan Hopper, Karen Mahoney; 2023 – Joe Mara, Michael Halpin, Jonathan Hopper, Sean Flynn; 2022 – Joe Mara, Michael Halpin, Sean Flynn, Jonathan Hopper; 2021 – Joe Mara, Michael Halpin, Sean Flynn, Jonathan Hopper, Sandra Pennell; 2020 – Michael Halpin, Sean Flynn, Jonathan Hopper, Gerard Michel, Sandra Pennell.
Peer Group Issuers, Footnote |  | TSR is cumulative for the measurement period, calculated in accordance with Item 201(e) of Regulation S-K. Our TSR Peer Group are members of the NASDAQ Biotechnology Index. |  |  |  |
PEO Total Compensation Amount |  | $ 10,237,525 | $ 7,056,422 | $ 8,708,367 | $ 13,183,295 | $ 4,412,718
PEO Actually Paid Compensation Amount | [1] | $ 18,758,303 | 11,004,672 | 905,166 | 15,233,917 | 10,300,425
Adjustment To PEO Compensation, Footnote [Text Block] |  |
|  |  |  | CEO
|  |  |  | 2020 |  |  | 2021 |  |  | 2022 |  |  | 2023 |  |  | 2024 |
|  | Summary Compensation Table Total |  | $ | 4,412,718 |  |  | $ | 13,183,295 |  |  | $ | 8,708,367 |  |  | $ | 7,056,422 |  |  | $ | 10,237,525 |
Less: |  | Grant Date Fair Value of Stock and Option Awards in the Covered Year |  | -$ | 3,218,783 |  |  | -$ | 11,819,409 |  |  | -$ | 7,288,603 |  |  | -$ | 5,513,083 |  |  | -$ | 8,680,435 |
Plus: |  | Fair Value at Year-End of Unvested Stock and Option Awards Granted in the Covered Year* |  | +$ | 5,022,331 |  |  | +$ | 6,387,501 |  |  | +$ | 4,402,751 |  |  | +$ | 5,834,763 |  |  | +$ | 8,700,718 |
Plus: |  | Fair Value of Stock and Option Awards Granted in the Covered Year that Vested in the Covered Year* |  | +$ | 522,347 |  |  | +$ | 1,618,248 |  |  | +$ | 724,137 |  |  | +$ | 711,181 |  |  | +$ | 1,038,836 |
|  | Change in Fair Value of Unvested Stock and Option Awards Granted in Prior Years* |  | +$ | 3,550,577 |  |  | +$ | 1,965,721 |  |  | -$ | 3,564,080 |  |  | +$ | 1,963,617 |  |  | +$ | 4,861,123 |
|  | Change in Fair Value of Stock and Option Awards from Prior Years that Vested in the Covered Year* |  | +$ | 11,235 |  |  | +$ | 3,898,560 |  |  | -$ | 2,077,406 |  |  | +$ | 951,771 |  |  | +$ | 2,600,537 |
= |  | Compensation Actually Paid |  | $ | 10,300,425 |  |  | $ | 15,233,917 |  |  | $ | 905,166 |  |  | $ | 11,004,672 |  |  | $ | 18,758,303 |
Non-PEO NEO Average Total Compensation Amount | [2] | $ 2,703,655 | 1,918,083 | 2,398,900 | 3,459,670 | 1,158,216
Non-PEO NEO Average Compensation Actually Paid Amount | [1],[2] | $ 4,246,598 | 2,851,775 | 467,192 | 3,204,518 | 1,740,344
Adjustment to Non-PEO NEO Compensation Footnote |  |
|  |  |  | Average of Other NEOs
|  |  |  | 2020 |  |  | 2021 |  |  | 2022 |  |  | 2023 |  |  | 2024 |
|  | Summary Compensation Table Total |  | $ | 1,158,216 |  |  | $ | 3,459,670 |  |  | $ | 2,398,900 |  |  | $ | 1,918,083 |  |  | $ | 2,703,655 |
Less: |  | Grant Date Fair Value of Stock and Option Awards in the Covered Year |  | -$ | 714,993 |  |  | -$ | 2,945,499 |  |  | -$ | 1,748,862 |  |  | -$ | 1,198,907 |  |  | -$ | 2,049,743 |
Plus: |  | Fair Value at Year-End of Unvested Stock and Option Awards Granted in the Covered Year* |  | +$ | 756,348 |  |  | +$ | 1,626,544 |  |  | +$ | 1,056,425 |  |  | +$ | 1,275,999 |  |  | +$ | 2,095,233 |
Plus: |  | Fair Value of Stock and Option Awards Granted in the Covered Year that Vested in the Covered Year* |  | +$ | 83,133 |  |  | +$ | 271,626 |  |  | +$ | 173,955 |  |  | +$ | 147,705 |  |  | +$ | 180,724 |
|  | Change in Fair Value of Unvested Stock and Option Awards Granted in Prior Years* |  | +$ | 636,734 |  |  | +$ | 299,760 |  |  | -$ | 902,246 |  |  | +$ | 445,775 |  |  | +$ | 832,854 |
|  | Change in Fair Value of Stock and Option Awards from Prior Years that Vested in the Covered Year* |  | +$ | 5,675 |  |  | +$ | 594,099 |  |  | -$ | 510,980 |  |  | +$ | 263,119 |  |  | +$ | 483,874 |
Less: |  | Fair Value of Stock and Option Awards Forfeited During the Covered Year* |  | -$ | 184,769 |  |  | -$ | 101,683 |  |  | +$ | 0 |  |  | +$ | 0 |  |  | +$ | 0 |
= |  | Compensation Actually Paid |  | $ | 1,740,344 |  |  | $ | 3,204,518 |  |  | $ | 467,192 |  |  | $ | 2,851,775 |  |  | $ | 4,246,598 |
Compensation Actually Paid vs. Total Shareholder Return |  | Compensation Actually Paid versus TSR 2020-2024 |  |  |  |
Compensation Actually Paid vs. Net Income |  | Compensation Actually Paid versus Net Income 2020-2024 |  |  |  |
Compensation Actually Paid vs. Company Selected Measure |  | Compensation Actually Paid versus Revenue 2020-2024 |  |  |  |
Total Shareholder Return Vs Peer Group |  |  |  |  |  |
Tabular List, Table |  | ### Tabular List of Financial Performance Measures The following measures in our assessment represent the most important financial performance measures that link compensation actually paid to our named executive officers, for 2024, to Vericel’s performance:
1. | Total Net Revenue
2. | Stock Price
3. | Budget expense (excluding depreciation, amortization and stock-based compensation, and unusual one-time expenses or changes in accounting methodology)
Total Shareholder Return Amount | [3] | $ 316 | 205 | 151 | 226 | 177
Peer Group Total Shareholder Return Amount | [3] | 114 | 115 | 111 | 125 | 126
Net Income (Loss) Attributable to Parent | [4] | $ 10,000,000 | $ (3,000,000) | $ (17,000,000) | $ (7,000,000) | $ 3,000,000
Company Selected Measure Amount | [5] | 237,000,000 | 198,000,000 | 164,000,000 | 156,000,000 | 124,000,000
Measure [Axis]: 1 |  |  |  |  |  |
Pay vs Performance Disclosure [Table] |  |  |  |  |  |
Measure Name |  | Total Net Revenue |  |  |  |
Measure [Axis]: 2 |  |  |  |  |  |
Pay vs Performance Disclosure [Table] |  |  |  |  |  |
Measure Name |  | Stock Price |  |  |  |
Measure [Axis]: 3 |  |  |  |  |  |
Pay vs Performance Disclosure [Table] |  |  |  |  |  |
Measure Name |  | Budget expense (excluding depreciation, amortization and stock-based compensation, and unusual one-time expenses or changes in accounting methodology) |  |  |  |
PEO [Member] | Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member] |  |  |  |  |  |
Pay vs Performance Disclosure [Table] |  |  |  |  |  |
Adjustment to Compensation Amount |  | $ (8,680,435) | $ (5,513,083) | $ (7,288,603) | $ (11,819,409) | $ (3,218,783)
PEO [Member] | Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member] |  |  |  |  |  |
Pay vs Performance Disclosure [Table] |  |  |  |  |  |
Adjustment to Compensation Amount | [6] | 8,700,718 | 5,834,763 | 4,402,751 | 6,387,501 | 5,022,331
PEO [Member] | Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member] |  |  |  |  |  |
Pay vs Performance Disclosure [Table] |  |  |  |  |  |
Adjustment to Compensation Amount | [6] | 1,038,836 | 711,181 | 724,137 | 1,618,248 | 522,347
PEO [Member] | Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member] |  |  |  |  |  |
Pay vs Performance Disclosure [Table] |  |  |  |  |  |
Adjustment to Compensation Amount | [6] | 4,861,123 | 1,963,617 | (3,564,080) | 1,965,721 | 3,550,577
PEO [Member] | Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member] |  |  |  |  |  |
Pay vs Performance Disclosure [Table] |  |  |  |  |  |
Adjustment to Compensation Amount | [6] | 2,600,537 | 951,771 | (2,077,406) | 3,898,560 | 11,235
Non-PEO NEO [Member] | Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member] |  |  |  |  |  |
Pay vs Performance Disclosure [Table] |  |  |  |  |  |
Adjustment to Compensation Amount |  | (2,049,743) | (1,198,907) | (1,748,862) | (2,945,499) | (714,993)
Non-PEO NEO [Member] | Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member] |  |  |  |  |  |
Pay vs Performance Disclosure [Table] |  |  |  |  |  |
Adjustment to Compensation Amount | [6] | 2,095,233 | 1,275,999 | 1,056,425 | 1,626,544 | 756,348
Non-PEO NEO [Member] | Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member] |  |  |  |  |  |
Pay vs Performance Disclosure [Table] |  |  |  |  |  |
Adjustment to Compensation Amount | [6] | 180,724 | 147,705 | 173,955 | 271,626 | 83,133
Non-PEO NEO [Member] | Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member] |  |  |  |  |  |
Pay vs Performance Disclosure [Table] |  |  |  |  |  |
Adjustment to Compensation Amount | [6] | 832,854 | 445,775 | (902,246) | 299,760 | 636,734
Non-PEO NEO [Member] | Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member] |  |  |  |  |  |
Pay vs Performance Disclosure [Table] |  |  |  |  |  |
Adjustment to Compensation Amount | [6] | 483,874 | 263,119 | (510,980) | 594,099 | 5,675
Non-PEO NEO [Member] | Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member] |  |  |  |  |  |
Pay vs Performance Disclosure [Table] |  |  |  |  |  |
Adjustment to Compensation Amount | [6] | $ 0 | $ 0 | $ 0 | $ (101,683) | $ (184,769)
[1] | To calculate CAP, the following amounts were deducted from and added to the applicable Summary Compensation Table total compensation:
[2] | The other NEOs in each covered year were as follows: 2024 – Joe Mara, Michael Halpin, Sean Flynn, Jonathan Hopper, Karen Mahoney; 2023 – Joe Mara, Michael Halpin, Jonathan Hopper, Sean Flynn; 2022 – Joe Mara, Michael Halpin, Sean Flynn, Jonathan Hopper; 2021 – Joe Mara, Michael Halpin, Sean Flynn, Jonathan Hopper, Sandra Pennell; 2020 – Michael Halpin, Sean Flynn, Jonathan Hopper, Gerard Michel, Sandra Pennell.
[3] | TSR is cumulative for the measurement period, calculated in accordance with Item 201(e) of Regulation S-K. Our TSR Peer Group are members of the NASDAQ Biotechnology Index.
[4] | Reflects net Income as shown in the Company’s Annual Report on Form 10-K for the years ending on December 31, 2024, 2023, 2022, 2021 and 2020.
[5] | Reflects total net revenue, the “company-selected measure” as shown in the Company’s Annual Report on Form 10-K for the years ending on December 31, 2024, 2023, 2022, 2021 and 2020.
[6] | All stock option valuations included in “Compensation Actually Paid” values were performed using the Black-Scholes option pricing model in a manner generally consistent with the process used to determine stock option grant date fair values under ASC718 (refer to our Annual Report on Form 10-K for the year ending December 31, 2024 for additional detail).

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 3 + Details
Name: | ecd_AdjToCompAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 3 + Details
Name: | ecd_AdjToNonPeoNeoCompFnTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 3 + Details
Name: | ecd_AdjToPeoCompFnTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph vi + Details
Name: | ecd_CoSelectedMeasureAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:decimalItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph vi + Details
Name: | ecd_CoSelectedMeasureName
Namespace Prefix: | ecd_
Data Type: | xbrli:normalizedStringItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 5 -Subparagraph iii + Details
Name: | ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 5 -Subparagraph ii + Details
Name: | ecd_CompActuallyPaidVsNetIncomeTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 5 -Subparagraph i + Details
Name: | ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph vi + Details
Name: | ecd_MeasureName
Namespace Prefix: | ecd_
Data Type: | xbrli:normalizedStringItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 3 + Details
Name: | ecd_NamedExecutiveOfficersFnTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph iii + Details
Name: | ecd_NonPeoNeoAvgCompActuallyPaidAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph ii + Details
Name: | ecd_NonPeoNeoAvgTotalCompAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph iv + Details
Name: | ecd_PeerGroupIssuersFnTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph iv + Details
Name: | ecd_PeerGroupTotalShareholderRtnAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph iii + Details
Name: | ecd_PeoActuallyPaidCompAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph ii + Details
Name: | ecd_PeoTotalCompAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 1 + Details
Name: | ecd_PvpTable
Namespace Prefix: | ecd_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 1 + Details
Name: | ecd_PvpTableTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 6 + Details
Name: | ecd_TabularListTableTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph iv + Details
Name: | ecd_TotalShareholderRtnAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 5 -Subparagraph iv + Details
Name: | ecd_TotalShareholderRtnVsPeerGroupTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11 Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11 Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4 Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10 Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7 Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1 Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7 Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details
Name: | us-gaap_NetIncomeLoss
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | ecd_MeasureAxis=1
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_MeasureAxis=2
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_MeasureAxis=3
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_ExecutiveCategoryAxis=ecd_PeoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_ExecutiveCategoryAxis=ecd_NonPeoNeoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |